Introduction
Systems that modulate (trans)gene expression in mammalian cells and tissues are important for a wide variety of basic and applied biological research areas, including functional genomics, gene therapy, animal models for human diseases and biopharmaceutical protein production. All these applications require that the expression of the gene(s) of interest can be strictly controlled in a quantitative and temporal manner. Several artificial gene expression systems that are regulated by nontoxic effector molecules in a dose-dependent and reversible manner are currently available. 1 The Tet system, in which gene expression is stringently controlled by tetracycline (Tc) or its derivative doxycycline (dox), is the most widely used regulatory circuit. [2] [3] [4] This system is based on the sequence-specific, high-affinity binding of the Escherichia coli Tet repressor protein (TetR) to the tet operator (tetO) DNA sequence. Tc or dox binds to TetR and triggers a conformational change that prevents the repressor protein from binding to tetO. Fusion of the VP16 activation domain of herpes simplex virus to TetR resulted in the transcriptional activator tTA, which induces gene expression from tetO-containing promoters (P tet ) in eukaryotic cells. 5 The presence of Tc or dox abolishes tTA-tetO interaction and switches off gene expression (Tet-Off system). A tTA variant with four amino-acid substitutions in the TetR moiety was identified, which exhibits a reverse phenotype. 6 This reversetTA (rtTA) binds to P tet exclusively in the presence of dox, but not in its absence (Tet-On system). Both Tet systems are now widely applied to control gene expression in eukaryotes, including mammals, plants and insects (reviewed in Gossen and Bujard 3 ). As longterm exposure to effectors is often undesirable, the Tet-On system is preferred in applications in which gene expression is to be sustained in a switched-off state for long periods, or when rapid gene induction is required. 6, 7 Unfortunately, the amino-acid substitutions in rtTA that confer the reverse phenotype also affect its overall performance. As a consequence, rtTA has lost the ability to be activated by Tc and other dox-like compounds, and it requires 100-fold more dox for maximal induction than that is needed for tTA inhibition. 2 These characteristics severely limit the in vivo use of the Tet-On system. 8, 9 For example, to activate Tet-On controlled transgene expression in the rat brain, animals received a high dose of dox that is nearly toxic. 9 Therefore, the Tet-On system, particularly its effector-sensitivity, needs to be improved significantly. Previously, the Tet system has been optimized by the introduction of rationally designed mutations, 10, 11 or by random mutagenesis followed by functional screening in bacterial or yeast assay systems. 6, 12 However, these approaches are labor intensive, and mutations selected in bacterial or yeast assay systems are not necessarily improvements in higher eukaryotes.
We recently presented viral evolution as a novel and powerful method to optimize the Tet-On system for its function in mammalian cells. 13 The components of the Tet-On system were incorporated into the human immunodeficiency virus (HIV)-1 genome such that viral replication is controlled by this regulatory circuit. During replication of this HIV-rtTA in human T cells, genetic diversity is continuously generated due to the errorprone reverse transcription process, followed by outgrowth of faster replicating variants. Thus, generation of genetic diversity and selection of improved variants are combined in this viral evolution approach. We previously described the selection of a virus variant with enhanced replication capacity due to a specific aminoacid change in the rtTA protein. 13 This mutant rtTA did not only improve viral replication, but was also a general improvement of the Tet-On system. This result demonstrated the proof of principle and the power of the viral evolution strategy. We now performed extensive viral evolution experiments to further improve the Tet-On system and describe the isolation of novel rtTA variants with greatly improved transcriptional activity and doxsensitivity. Combining the beneficial mutations resulted in rtTA variants that are seven-fold more active and 100-fold more dox-sensitive than the original Tet-On system.
Results

rtTA variants selected during continuous viral evolution of HIV-rtTA
We have previously reported on the construction of an infectious HIV-rtTA virus that is critically dependent on dox for replication. 14, 15 In this virus, the natural transcriptional activator Tat and its TAR binding site were inactivated by mutation and functionally replaced by the components of the Tet-On system (Figure 1a) . The gene encoding the transcriptional activator rtTA was inserted in place of the nef gene, and the tetO DNA binding sites were introduced in the viral LTR promoter. This virus does not replicate in the absence of dox. Upon dox administration, rtTA activates transcription from the LTR-tetO promoter, resulting in expression of the viral proteins and subsequent viral replication. We previously reported that a characteristic change in the LTR-tetO promoter, which occurred in multiple, independent longterm virus cultures, significantly improved HIV-rtTA replication. 16, 17 In addition, we selected an HIV-rtTA variant with improved replication capacity, which had acquired amino-acid substitutions (F86Y and A209T) in the rtTA protein. Further analysis revealed that the F86Y mutation enhanced the transcriptional activity and doxsensitivity of rtTA. 13 Encouraged by these results, we decided to exploit the viral evolution strategy to further improve the Tet-On system. We therefore started multiple, independent virus cultures of the HIV-rtTA F86Y A209T variant, which contains both the optimized LTR-tetO promoter configuration and the improved rtTA gene. After culturing the virus with dox for up to 200 days, the rtTA gene was sequenced. The F86Y and A209T mutations were stably maintained in all analyzed cultures. Several viruses from independent cultures had acquired additional mutations in the rtTA gene. A virus variant should have a replication advantage to become the dominant sequence in a virus population. Mutations in rtTA may improve rtTA function, and thus enhance viral replication. To increase the chance of identifying such beneficial mutations, we focused on the rtTA mutations that were selected in multiple cultures (Figure 1a ; Table 1 ). All these aminoacid substitutions are located in the TetR part of rtTA: V9I is in the a1 helix within the DNA-binding domain, F67S is in the loop following a4, and G138D, E157K and R171K are within the a8-a9 region of the regulatory core domain (Figure 1b) . V9I was found both as an individual mutation and in combination with G138D, E157K or . rtTA is based on class B (TetR B ), which shares 63% sequence identity with TetR D . The crystal structure of TetR B at medium resolution revealed an identical polypeptide fold. 21 Therefore, we can assume that the interactions of TetR with Tc and Mg 2+ will be nearly identical in both classes. The figures are drawn using the 2TCT coordinates from the Protein Data Bank and the MOLSCRIPT 36 and RASTER3D 37 programs.
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R171K. A combination of F67S and R171K was also observed. There are seven natural variants of TetR (A-E, G, H) and rtTA is based on class B (TetR B ). Interestingly, only TetR
B has a Phe at position 67, whereas most TetRs have a Ser at this position (Table 1) . Other amino-acid substitutions observed in the evolved rtTAs are never present in natural TetR variants.
Characterization of the evolved rtTA variants
To test whether the evolved rtTAs exhibit improved transcriptional activity, we assayed rtTA activity in a regular Tet system. Expression plasmids encoding the original (wild type) and mutant rtTA proteins (V1-V10, Table 1 ) were constructed and transfected into C33A cells with a plasmid expressing the luciferase reporter under the control of the viral LTR-2DtetO promoter. Cells were cultured with different dox concentrations, and the luciferase level measured 2 days after transfection reflects rtTA activity (Figure 2a ). In the absence of dox, the luciferase level observed with the wild type and all mutant rtTAs is similar to the level observed with a control plasmid that does not express rtTA (pBluescript, À). This result demonstrates that the original and novel rtTA variants do not show detectable basal activity in the absence of dox. Wild-type rtTA activity is detectable first at 500 ng/ml dox and increases further at 1000 ng/ml. Consistent with our previous study, 13 rtTA V1 (F86Y A209T) activity is already detectable at 50 ng/ml dox and gradually increases with higher dox concentrations. At 1000 ng/ml dox, the V1 variant is 2.5-fold more active than the wild type. All other mutant rtTAs did evolve from V1, and their activity should thus be compared with this variant. rtTA V2 is more active than V1 at the lowest dox concentration tested, but less active at high dox levels. The other rtTAs with a single amino-acid substitution (V3-V6) are more active than V1 both at low and high dox levels. The variants V7, V8 and V9 combine the V2 mutation with the V4, V5 and V6 mutation, respectively. These combinations further improve rtTA activity both at low and high dox levels. The V10 variant that combines the V3 and V6 mutations is the most active rtTA of the naturally evolved variants. Therefore, the viral evolution strategy resulted in several novel rtTA variants with enhanced transcriptional activity and doxsensitivity compared with wild-type rtTA and the V1 variant that was used to start the evolution experiment.
To test whether this rtTA optimization reflects a specific adaptation to the viral LTR-2DtetO promoter, we assayed rtTA activity with a standard reporter gene construct that expresses luciferase under the control of a minimal CMV promoter coupled to an array of seven tetO elements. 5 All evolved rtTA variants demonstrate improved activity with this promoter construct ( Figure  2b) , which mimics the result with the HIV LTR-2DtetO construct (Figure 2a) . Thus, the observed mutations in rtTA are not virus-specific adaptations, but general improvements of the Tet-On system. We also assayed rtTA activity in HeLa X1/6 cells that contain chromosomally integrated copies of the CMV-7tetO luciferase reporter construct (Figure 2c ). In these cells, the evolved rtTAs show a similar pattern of activity as with episomal reporter gene constructs in C33A cells. Thus, these mutations improve rtTA activity independent of the type of promoter and the episomal or chromosomal status of the target gene.
To compare the dox-sensitivity of the rtTA variants, we calculated the dox concentration that each rtTA variant needs to reach an activity similar to that of the wild-type rtTA at 1000 ng/ml dox ( Figure 3 ). The V10 variant needs only 44 ng/ml dox to reach this activity level, which reflects a 23-fold higher dox-sensitivity than 
Abbreviations: rtTA, reverse-tTA; TetR, Tet repressor protein.
a
The wild-type rtTA was previously described as rtTA2 S -S2. All variants (V1-V18) contain the mutations F86Y (in the TetR domain) and A209T (in the VP16 activation domain).
13
Optimization of the Tet-On system X Zhou et al the wild-type rtTA. This makes the V10 variant the most dox-sensitive and most active rtTA (6.6-fold more active than the wild type, Figure 3 ) of the naturally evolved variants.
Combining beneficial mutations further improves rtTA activity
Analysis of the evolved rtTA variants revealed that the double mutants are more active and dox-sensitive than Figure 2 Novel rtTA variants show increased activity and doxycycline (dox)-sensitivity in different Tet systems. The transcriptional activity of rtTA variants was measured in C33A cells transfected with a plasmid expressing firefly luciferase reporter under the control of the viral LTR2DtetO promoter (LTR-2DtetO; a) or under the control of a minimal CMV-derived promoter coupled to seven tetO elements (CMV-7tetO; b). Furthermore, rtTA activity was measured in HeLa X1/6 cells 10 that contain chromosomally integrated copies of the CMV-7tetO reporter construct (CMV-7tetO-integrated; c, d). Variants V1 to V10 were compared in all three Tet systems (panels a-c) and variants V11 to V18 in the cells with the integrated reporter (d). Cells were transfected with the indicated rtTA expression plasmid or pBluescript as a negative control (À) and a plasmid constitutively expressing Renilla luciferase to correct for differences in transfection efficiency. Cells were cultured in the presence of different dox concentrations (0-1000 ng/ml). The ratio of the firefly and Renilla luciferase activities measured two days after transfection reflects the rtTA activity. All values were related to the wild-type (wt) rtTA activity at 1000 ng/ml dox, which was arbitrarily set at 100%. In panels c and d, average values of three transfections are shown with the error bar indicating the standard deviation.
Optimization of the Tet-On system X Zhou et al the single mutants. For instance, V6 (R171K) is 4.4-fold more sensitive than the wild-type rtTA, and the double mutant V9 (V9I R171K) is 14.9-fold more dox-sensitive. We therefore constructed additional rtTA variants in which beneficial mutations were combined (V11-V18, Table 1 ), and assayed their activity ( Figure 2d ). As shown in Figure 3 , all combination variants demonstrate a higher transcriptional activity and dox-sensitivity than the naturally evolved variants. The triple mutants V14, V15, and V16 are the most active and most dox-sensitive rtTAs. They are seven-fold more active at high dox levels and 100-fold more sensitive to dox when compared with wild-type rtTA. The V15 and V16 variants show no activity without dox, whereas we frequently observed a low, but distinct basal activity with the V14 variant (less than 0.1% of the induced level).
To exclude the possibility that the enhanced activity observed for the mutant rtTAs resulted from an increased protein level, we determined the intracellular steady-state level of the rtTA proteins. Lysates of HeLa X1/6 cells transfected with rtTA expression plasmids were subjected to sodium dodecyl-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blot analysis with polyclonal anti-TetR antibodies. An equal amount of rtTA protein was detected for all naturally evolved and constructed variants ( Figure 4 and results not shown). These results indicate that the enhanced activity and dox-sensitivity are intrinsic properties of the mutant rtTA proteins and do not result from increased expression or protein stability.
Novel rtTA variants can be activated by dox-like compounds
Dox is the most efficient effector that controls the Tet-On system. 6 Other dox-like compounds, such as Tc and minocycline (Mc), do not effectively activate the wildtype rtTA protein. To test whether the novel rtTA variants with improved activity and dox-sensitivity have a Figure 3 Transcriptional activity and doxycycline (dox)-sensitivity of the naturally evolved and constructed rtTA variants. The transcriptional activity of all rtTA variants at 1000 ng/ml dox as measured in Figure 2c and d is shown in the left panel (wild-type rtTA activity set at 100%). We calculated the dox concentration that each rtTA variant needs to reach an activity comparable to that of the wild-type rtTA at 1000 ng/ml dox by interpolation of the data from Figure 2c and d. These concentrations are indicated between brackets in the right panel (ND, not determined), and were used to calculate the dox-sensitivity for each rtTA variant (dox-sensitivity of wild-type rtTA set at 1). Figure 4 Mutations do not affect the intracellular rtTA protein level. HeLa X1/6 cells were transfected with the indicated rtTA expression plasmid (lanes 3-6) or pBluescript as a negative control (lane 2). Total cellular extracts were prepared at two days after transfection and analyzed on Western blot that was stained with polyclonal anti-TetR rabbit serum. 35 Detection of purified TetR protein (2 ng) is shown in lane 1. The position and molecular weight (in kDa) of the rtTA and TetR proteins are indicated.
Optimization of the Tet-On system X Zhou et al broader effector-specificity, we assayed the activity of a subset of these rtTA variants at different Tc and Mc concentrations ( Figure 5 ). Whereas Tc and Mc do not activate the wild-type rtTA and the V1 variant, mutant V3 shows a low level of activity at a high Tc or Mc concentration (10 000 ng/ml). V7 activity is already detectable at 1000 ng/ml Tc or Mc, and the activity increases at higher effector levels. V14 that combines the V3 and V7 mutations shows the highest activity with Tc and Mc. The activity at 10 000 ng/ml Tc is similar to that of the wild-type rtTA at 1000 ng/ml dox. At 1000 ng/ml Mc, V14 is even more active than the wild-type rtTA at 1000 ng/ml dox. Thus, we have generated rtTA variants with a broader effector-specificity.
Discussion
Viral evolution can be used as a tool to improve the activity of proteins if one can make them an integral and essential part of the viral replication machinery. We used this approach to improve the widely used Tet-On system for inducible gene expression. Upon long-term in vitro culturing of the HIV-rtTA virus, in which gene expression and viral replication is controlled by the incorporated Tet-On system, several mutations in the rtTA gene were observed. We demonstrate that these mutations do not affect the intracellular expression of rtTA, but strongly enhance the transcriptional activity and doxsensitivity of the protein. This improvement was observed with different tetO-containing promoters and was independent of the episomal or chromosomal status of the target gene. Combining the naturally evolved mutations resulted in further improved rtTA variants. The most optimal variants (V15 and V16) are seven-fold more active at high dox levels and 100-fold more sensitive to dox than the original rtTA. Importantly, these rtTA variants do not show detectable basal activity in the absence of dox. High activity and dox-sensitivity of these novel rtTAs significantly improve the performance of the Tet-On system, which is now comparable to the performance of the Tet-Off system. For example, rtTA V16 requires approximately 5 ng/ml dox to be as active as tTA in the absence of dox, whereas tTA requires approximately 10 ng/ml dox to be switched off (Baron and Bujard 2 and results not shown). Furthermore, like the original Tet-Off system, some of the new Tet-On systems are responsive to Tc and Mc. These improved rtTA variants are particularly suitable for in vivo applications that require a more sensitive or more active Tet-On system, for example in gene therapy approaches in tissues such as the brain, where relatively low dox levels can be reached. 9 Moreover, these rtTA variants significantly improve replication of the HIV-rtTA virus, [18] [19] [20] which was proposed as a conditional-live virus vaccine (results not shown).
All observed mutations are located in the TetR domain of rtTA. There are seven natural TetR variants (A-E, G, H) with a highly conserved sequence, and the rtTA protein is based on class B (Table 1 ). The crystal structure of the rtTA protein has not been solved, but the structure of the TetR protein, bound either to Tc or tetO DNA, is known. [21] [22] [23] [24] The Val residue at position 9 is part of the hydrophobic core that stabilizes the DNA-binding domain (Figure 1b) . Replacement of Val by Ile, conserving the hydrophobic nature of this residue, may affect the orientation of the DNA-binding domain and its affinity for tetO. Interestingly, most TetR classes have a Ser residue at position 67 that forms a hydrogen bond with the conserved, Tc-interacting residue Gln116. 22 The Phe-67-Ser mutation could thus indirectly stimulate effector binding. The amino acid at position 138 is not in direct contact with Tc in the crystal structure, but it is in close proximity to the effector, and recent mutagenesis studies showed that mutations at this position dramatically affect TetR activity. 25 Thus, the Gly-138-Asp mutation may directly improve binding of the effector molecule. Residue 138 is also in close proximity to residue 86, 25 and all new rtTA variants carry the Phe-86-Tyr mutation. Therefore, the Gly-138-Asp mutation could also be an adjustment for the Phe-86-Tyr mutation, and thus indirectly improve rtTA activity.
The loop connection between helix a8 and a9 (residues 155-167) is highly flexible in the TetR crystal structure. 23 This loop is also the least conserved region in different TetR classes. However, residue 157 is always negatively charged (Asp or Glu) and important for induction. 26 A Glu-157-Lys mutation in TetR reduced its inducibility three-fold. 27 The same Glu to Lys mutation increased rtTA activity (this study), suggesting that the mutation specifically improves the reverse phenotype of rtTA. Residue 171 is located in helix a9, which wraps around ). Except for the F86Y and G138D mutations, none of the evolved residues are located in the vicinity of each other in the TetR crystal structure, such that direct interactions between these residues are unlikely. Therefore, the higher activity and sensitivity observed upon combination of beneficial mutations may be explained by an additive effect of each individual mutation.
The results of this study underline the genetic flexibility of HIV-rtTA, which can be further exploited for the functional modification of the Tet-On system and to further improve the HIV-rtTA vaccine virus. For instance, long-term replication of HIV-rtTA with Tc and Mc may eventually select for rtTA variants that respond exclusively to these non-dox compounds. These rtTA variants will help in the generation of new regulatory circuits that allow independent regulation of multiple (trans)genes with different effector molecules. Adapting HIV-rtTA to dox-like compounds lacking antibiotic activity may result in rtTA variants that can no longer be induced by common antibiotics. Using such Tet systems with nonantibiotic effectors in vivo will avoid disturbance of the bowel flora. Furthermore, dox-like antibiotics can still be used to treat bacterial infections without unintentionally activating the Tet system.
Materials and methods
Cell cultures
The human T-lymphocyte cell line SupT1 29 was cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), penicillin (100 U/ml), and streptomycin (100 mg/ml). HeLa X1/6 10 is a HeLa-derived cervix carcinoma cell line containing chromosomally integrated copies of the CMV-7tetO luciferase reporter construct pUHC13-3.
5 HeLa X1/6 and C33A cervix carcinoma cells (ATCC HTB31) 30 were grown in Dulbecco's modified Eagle's medium supplemented with 10% FCS, minimal essential medium nonessential amino acids, penicillin (100 U/ml), and streptomycin (100 mg/ml). All cell cultures were kept at 371C and 5% CO 2 .
Virus replication
Construction of the HIV-rtTA molecular clone was described previously. 14, 15 For the selection of evolved viruses, SupT1 cells were transfected with the HIVrtTA F86Y A209T molecular clone by electroporation, and cultured in the presence of 1 mg/ml dox (Sigma D-9891, St Louis, MO, USA) for up to 200 days as described previously. 13 The virus containing culture supernatant was passaged onto fresh SupT1 cells at the peak of infection, as determined by the massive appearance of syncytia. At regular intervals, cell and supernatant samples were taken from the culture and stored at À801C for subsequent analysis.
Proviral DNA analysis and cloning of evolved sequences
Total cellular DNA from infected cells was isolated as described previously. 31 The proviral rtTA gene was amplified by polymerase chain reaction (PCR) with the sense primer tTA1 (5 0 -ACAGCCATAGCAGTAGCTGAG-3 0 ) and the antisense primer tTA-rev2 (5 0 -GATCAAGGA TATCTTGTCTTCGT-3 0 ), and sequenced with the bigdye terminator cycle sequencing kit (Applied Biosystems, Foster City, CA, USA). The PCR products were digested with XbaI and SmaI and used to replace the corresponding fragment in pCMV-rtTA, in which the expression of wild-type rtTA (rtTA2 S -S2 12 ) is controlled by the human cytomegalovirus (CMV) immediate-early promoter. To introduce the F67S and G138D mutations into evolved rtTA variants, mutagenesis PCR 32 was performed on the corresponding pCMV-rtTA plasmid with the mutagenic primer (primer M) tTA-F67S (5 0 -CATACCCACTCCTGC CCCCTGGAAGGCGA-3 0 , mutated nucleotide underlined) or tTA-G138D (5 0 -GTCCGCCGTGGACCACTTTA CACTGGGCT-3 0 ) and the general primers 5 0 -TGGAGA CGCCATCCACGCT-3 0 (primer 1), 5 0 -TGAAATCGAGTT TCTCCAGGCCACATATGA-3 0 (primer 2), and 5 0 -TCAC TGCATTCTAGTTGTGGT-3 0 (primer 3). Briefly, PCR reactions were performed with primer M plus primer 3, and with primer 1 plus primer 2. The PCR products were purified, mixed, and PCR amplified with primers 1 and 3 (see Mikaelian and Sergeant 32 for details). The resulting mutated rtTA genes were cloned as EcoRIBamHI fragments into pCMV-rtTA. All constructs were verified by sequence analysis.
rtTA activity assay
Two firefly luciferase reporter constructs with different promoter configurations were used. pLTR-2DtetO-luc contains the LTR-2DtetO promoter derived from the HIV-rtTA molecular clone. 16, 17 pCMV-7tetO-luc, previously named pUHC13-3, 5 contains seven tetO elements located upstream of a minimal CMV promoter. The plasmid pRL-CMV (Promega, Madison, WI, USA) expressing Renilla luciferase under the control of the CMV promoter was used as an internal control to allow correction for differences in transfection efficiency.
C33A and HeLa X1/6 cells were grown in 2-cm 2 wells to 60% confluency and transfected by the calcium phosphate precipitation method.
33 C33A cells were transfected with 0.4 ng pCMV-rtTA (wild-type or mutant), 20 ng pLTR-2DtetO-luc or pCMV-7tetO-luc, 0.5 ng pRL-CMV, and 980 ng pBluescript as carrier DNA. HeLa X1/6 cells were transfected with 8 ng pCMV-rtTA, 2.5 ng pRL-CMV, and 990 ng pBluescript. The amount of the DNA constructs was optimized for each cell type to keep rtTA-mediated transactivation within the linear range and to avoid squelching of transcription factors. Cells were cultured for 48 h in the presence of different concentrations of dox, Tc (Sigma T-3383), or Mc (Sigma M-9511), and lysed in Passive Lysis Buffer (Promega). Firefly and Renilla luciferase activities were determined with the dual-luciferase reporter assay (Promega). The activity of the rtTA variants was calculated as the ratio of the firefly and Renilla luciferase activities, and corrected for between-session variation. 34 
Western blot analysis
HeLa X1/6 cells were transfected at 90% confluency with 1 mg wild type or mutant pCMV-rtTA and 2 ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in 2-cm 2 wells. Cells were cultured for 48 h and lysed in 100 ml Passive Lysis Buffer. Ten microliters of the lysate was Optimization of the Tet-On system X Zhou et al subjected to SDS-PAGE, and transferred onto Immobilon-P membrane (Millipore, Billerica, MA, USA). For immunochemical detection of rtTA variants, membranes were incubated with rabbit serum containing polyclonal anti-TetR antibodies. 35 Bound antibodies were visualized with peroxidase-linked anti-rabbit IgG and the ECL+ kit (Amersham Biosciences) and analyzed with a Storm 860 Imager (Amersham Biosciences, Freiburg, Germany).
